

Open Psychedelic Evaluation Nexus

Real-world Outcomes of Psychedelic Services

Adie Rae (Wilson-Poe), PhD

Co-Director, OPEN

Assistant Scientist, Legacy Research Institute






Disclosures


- No conflicts of interest
- Funding
 - OHSU Addiction Medicine Research Seed Grant
 - OHSU Foundation
 - SAMHSA 75S20123P000003
 - NIDA R01DA060253

OPEN's Project Ecosystem




OPEN

Expanding Legal Access



Adapted from Psychedelic Alpha, January 2026

Licensed Psilocybin Services Programs



Licensed Psilocybin Services Programs

	Oregon	Colorado
Cultivators	9	14
Laboratories	1	1
Service Centers	~21	~32
Facilitators	~344	~151
Clients Served	~15,000	???

Safety & Effectiveness: The Data Disconnect

Known:

Promising results:

- Traditional use
- Early phase trials
- Naturalistic use

Unknown:

Community settings:

- Similar safety?
- Similar outcomes?
- Equitable?

Purpose

Safety
Success
Equity



OPEN

Psychedelic Data:

A shared natural resource

- Purpose: Public wellbeing, shared wisdom
- Collective stewardship, not ownership
- Highest standards: encryption, confidentiality, security






OPEN Data Collection: Paradigm & Platform

Aims & Results

- **Goal**: Assess impact of state-regulated psilocybin services
- **Design**: Longitudinal cohort study of people receiving state-regulated psilocybin services
- **Outcome Measures**:
 - Severe adverse Reactions (Oregon regs)
 - Depression (PHQ-9)
 - Anxiety (HADS)
 - PTSD (PCL-6)
 - Wellbeing (Warwick Edinburgh Mental Wellbeing Scale)
 - Life Satisfaction
- **Analysis**: GEE baseline, 1-month, 3 months


OPEN Data Collection Strategy

A practice-based research network



Recruitment and retention

OPEN Client Cumulative Enrollment



*As of May 12, 2026

- Facilitators: n = **110**
 - 83 Oregon facilitators
 - 27 Colorado facilitators
- Licensed Service Centers: n = **32**
 - **24 of 26** Oregon service centers
 - **12 of 50** Colorado Healing Centers
- Clients: n = **475**
 - 417 Oregon clients
 - 58 Colorado clients
- Retention
 - **85%** or higher (all time points)

Facilitator Characteristics

	N=108
Mean age (years, SD)	46.3 (10.4)
Female gender	64%
Race/Ethnicity	
White	85%
Hispanic	6%
Heterosexual	64%
Professional licensure	70%
Education ≥ Masters	69%
Mean years experience facilitating	5.0 (6.1)
Lifetime use of psychedelics > 10 times	81%

Client Characteristics

Demographics	N=462
Mean age (years, SD)	49.4 (13.7)
Female gender	50%
Race/Ethnicity	
White	88%
Hispanic	6%
Heterosexual	85%
Veteran	6%
Education ≥ Bachelors	77%
Income ≥ \$200,000	31%
Reside outside OR/WA	53%


Substance Use	N=462
Psychedelic-naïve	45%
Alcohol Use, past 30d	61%
Tobacco/Nicotine, past 30d	12%
Cannabis Use, past 30d	36%

Mental Health Symptoms	N=462
Mod-Severe Anxiety (HADS)	44%
Mod-Severe Depression (PHQ9)	41%
Mod-Severe PTSD (PCL-6)	49%

Session Characteristics


- **N = 462**
- **Dose:** Mean = 31.2 mg (SD 12.6)
- **Individual sessions:** 82%
- **Group Sessions:** 18%

Reasons for Seeking Services



N = 290. Unpublished data, under review. Not for distribution

Participant-Reported Safety



Unpublished data. Not for distribution

Serious Adverse Reactions

- **N = 4/426 (1%)**
- **All behavioral reactions were psychedelic-naïve, seeking serves for mental health**
 - 1 **Facilitator** reported behavioral event on day of services – **50mg** psilocybin
 - Referred for same day psychiatric evaluation
 - Client rated experience as non-harmful, goals were met
 - 1 **Client** reported ER visit & new meds required - **25mg** psilocybin
 - Persistent psychological difficulties & thoughts of death at 3 months; rated experience as harmful; goals not met
 - 1 **Client** reported ER visit at 3 month - **25mg** psilocybin
 - Neutral regarding harms, benefits, and goals were met
 - 1 **Client** reported ER visit at 3 month & new meds required – **30mg** psilocybin
 - Felt experience was harmful, but also agreed on benefits, goals were met
- **2/4 clients ranked the experience among the most meaningful of their life**

Unpublished data. Not for distribution


Safety is Nuanced.

Adverse event reported to OHA:
Behavioral reaction, emergency services

But client reported no harms:

"I was really embarrassed about my behavior. But ultimately, the session was incredibly useful, and it's made a big positive impact on my life."


PRELIMINARY Data: Mental health



Mod-Severe Depression	%	RR (95% CI)
Baseline	41%	Ref
1 month	12%	0.29 (0.22-0.39)
3 months	16%	0.39 (0.32-0.49)

N = 290. Unpublished data, under review. Not for distribution


PRELIMINARY Data: Mental health



Mod-Severe Anxiety	%	RR (95% CI)
Baseline	46%	Ref
1 month	13%	0.28 (0.21-0.38)
3 months	14%	0.30 (0.23-0.38)

N = 290. Unpublished data, under review. Not for distribution

PRELIMINARY Data: Mental health



Mod-Severe PTSD	%	RR (95% CI)
Baseline	50%	Ref
1 month	20%	0.42 (0.34-0.52)
3 months	18%	0.36 (0.28-0.47)


N = 290. Unpublished data, under review. Not for distribution

PRELIMINARY Data: Wellbeing




OPEN

A



B



Wellbeing Score	Mean (SD)	Mean Difference (95% CI)
Baseline	22.2 (4.8)	Ref
1 month	26.3 (4.3)	4.14 (3.47-4.82)
3 months	25.4 (4.2)	3.21 (2.68-3.74)

Satisfied	%	RR (95% CI)
Baseline	63%	Ref
1 month	83%	1.32 (1.18-1.48)
3 months	83%	1.32 (1.18-1.47)

Unpublished data, under review. Not for distribution

Limitations

- Uncontrolled, observational design limits causal inference
 - But systematically collected descriptive data helpful
- Study population = ~10% of total clients receiving services in Oregon
 - But comparable demographics & 85% service centers suggest generalizability
- Does not reflect religious or unsupported use

Conclusions

- Rigorous real-world data to inform policy, consent
 - Confidential outcome tracking
 - Agnostic of geography, licensure, substance
- Early findings
 - Study population similar to clinical trials
 - Few, but notable safety events
 - Decrease in mental health symptoms (+pain)
 - Improved life satisfaction, wellbeing

Future Directions

- NIDA – substance use
- New Mexico & beyond
- Ibogaine
- Omnibus collaborations




OPEN

Thank you!

wilsonpoe@ohsu.edu

Adie Rae Wilson-Poe, PhD	Legacy Research Institute, OHSU
Todd Korthuis, MD, MPH	Oregon Health and Sciences University (OHSU)
Jason Luoma, PhD	Portland Psychotherapy Clinic, Research, & Training Center
Kim Hoffman, PhD	OHSU
Christopher Stauffer, MD	Portland Veterans Administration/OHSU
Dennis McCarty, PhD	OHSU
Don Des Jarlais, PhD	New York University
Ximena Levander, MD	OHSU
Ryan Cook, PhD	OHSU
Devin Gregoire, MS	OHSU
Kellie Pertl, MPH, CPH	OHSU







OPEN

Domain	Baseline	1 week	1 month	3 month	6 month	9 month	12 month
Demographics (12+)	X						
Administration Experiences							
Expectancy (6)	X						
Preparation (10)		X					
Therapeutic Alliance (5)		X					
Mystic/challenging experiences (11)		X					
Emotions scale (5)		X					
Administration Outcomes							
Safety (3-4) +expanded in 2026 ←		X	X	X	X	X	X
HPPD (1)			X	X	X	X	X
Integration (13)			X	X		X	
Service Satisfaction (4-8)		X	X		X		X
Sexual contact (1)		X			X		X
Mental Health							
Anxiety (7)	X		X	X	X	X	X
Depression (9)	X		X	X	X	X	X
Antidepressants (1)	X		X	X	X	X	X
PTSD (6)	X		X	X		X	
Substance Use							
Opioid DSM-5 (11)	X						
Δ in drug use (Drug of choice, 1)		X					X
Drug of choice (1)	X	X	X	X	X	X	X
Substance use (11+)	X		X	X	X	X	X
Psychedelic use (2+)	X		X	X	X	X	X
AUDIT-C (3)	X		X	X		X	
Tob use severity (4)	X		X	X		X	
e-Cig use severity (4)	X		X	X		X	
Drug use severity (7)	X		X		X		X
SUD treatment (1+)	X		X		X		X
QOL/Wellness							
Wellbeing (7)	X		X	X	X	X	X
Belonging (9)	X		X		X		X
Pain (3) +sleep in 2026 ←	X		X	X		X	
Life satisfaction (1)	X		X	X	X	X	X
Spirituality (5)	X		X		X		X